Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Comparison of efficacy of the implantable defibrillator in Europe and in the United States

01.09.2003


ESC Congress 2003



Sudden cardiac death from ventricular tachyarrhythmias is the leading cause of death in Europe and the US. It effects hundreds of thousands people each year. Many of them have known heart disease, mainly coronary artery disease. The implantable defibrillator (ICD) effectively treats such arrhythmias and prevents sudden cardiac death. Identification of patients at risk who may gain profit from prophylactic ICD implantation remains a difficult task for the cardiologist.

The Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) enrolled patients with a history of myocardial infarction and severely depressed left ventricular function without a history of life-threatening arrhythmias. The study was supported by an unrestricted research grant from GUIDANT, St.Paul, Minn. Patients were randomized to receive best medical therapy only or ICD implantation on top of best therapy. Over the course of four years 1232 patients were enrolled from 71 centers in the US and 5 centers in Europe. After a mean follow-up of 20 months, ICD therapy was associated with a 31 percent reduction in the risk of death.


In order to assess potential differences in clinical characteristics and outcome between European and US patients enrolled in the MADIT II trial ICD efficacy in the European patients was compared with US patients. European centers enrolled 109 (9%) of the total 1232 patients. European patients were younger, had a higher prevalence of symptomatic heart failure, but had a higher left ventricular ejection fraction than US patients. The percentage of female patients enrolled in MADIT II was lower in Europe than in the US (8% vs. 16%). Patients in Europe received more single chamber ICDs than US patients (86% vs. 53%). Also medications for the treatment of heart failure were slightly different in European and US patients.

During the course of the study, appropriate ICD therapy was similar in both groups. There was no difference in the incidence of arrhythmic death, heart failure death and overall mortality between European and US patients.

Although some differences in patient characteristics exist between patients enrolled in MADIT II in Europe and the United States with different rates of implantation of single vs. dual chamber ICD units, ICD efficacy seems to be similar in the two geographic regions.

Dr. Sven Reek
Univ. Hospitals Magdeburg, Div. of Cardiology
Germany

Important: This press release accompanies a poster or oral session given at the ESC Congress 2003. Written by the investigator himself/herself, this press release does not necessarily reflect the opinion of the European Society of Cardiology

Camilla Dormer | alfa
Further information:
http://www.escardio.org

More articles from Health and Medicine:

nachricht Spanish scientists create a 3-D bioprinter to print human skin
24.01.2017 | Carlos III University of Madrid

nachricht Tracking movement of immune cells identifies key first steps in inflammatory arthritis
23.01.2017 | Massachusetts General Hospital

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists spin artificial silk from whey protein

X-ray study throws light on key process for production

A Swedish-German team of researchers has cleared up a key process for the artificial production of silk. With the help of the intense X-rays from DESY's...

Im Focus: Quantum optical sensor for the first time tested in space – with a laser system from Berlin

For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.

According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Breaking the optical bandwidth record of stable pulsed lasers

24.01.2017 | Physics and Astronomy

Choreographing the microRNA-target dance

24.01.2017 | Life Sciences

Spanish scientists create a 3-D bioprinter to print human skin

24.01.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>